FI113862B - Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI113862B
FI113862B FI945042A FI945042A FI113862B FI 113862 B FI113862 B FI 113862B FI 945042 A FI945042 A FI 945042A FI 945042 A FI945042 A FI 945042A FI 113862 B FI113862 B FI 113862B
Authority
FI
Finland
Prior art keywords
hydrogen
compound
formula
lower alkyl
ring
Prior art date
Application number
FI945042A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945042A (fi
FI945042A0 (fi
Inventor
Klaus Boegesoe
Peter Bregnedal
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of FI945042A publication Critical patent/FI945042A/fi
Publication of FI945042A0 publication Critical patent/FI945042A0/fi
Application granted granted Critical
Publication of FI113862B publication Critical patent/FI113862B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
FI945042A 1992-04-28 1994-10-26 Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi FI113862B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK55192 1992-04-28
DK92551A DK55192D0 (da) 1992-04-28 1992-04-28 1-piperazino-1,2-dihydroindenderivater
PCT/DK1993/000136 WO1993022293A1 (en) 1992-04-28 1993-04-23 1-piperazino-1,2-dihydroindene derivatives
DK9300136 1993-04-23

Publications (3)

Publication Number Publication Date
FI945042A FI945042A (fi) 1994-10-26
FI945042A0 FI945042A0 (fi) 1994-10-26
FI113862B true FI113862B (fi) 2004-06-30

Family

ID=8094828

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945042A FI113862B (fi) 1992-04-28 1994-10-26 Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi

Country Status (24)

Country Link
US (1) US5807855A (de)
EP (1) EP0638073B1 (de)
JP (1) JP3255416B2 (de)
KR (1) KR100267635B1 (de)
AT (1) ATE194003T1 (de)
AU (1) AU669709B2 (de)
CA (1) CA2134566C (de)
CL (1) CL2003002050A1 (de)
CZ (1) CZ281676B6 (de)
DE (1) DE69328901T2 (de)
DK (2) DK55192D0 (de)
ES (1) ES2148227T3 (de)
FI (1) FI113862B (de)
GR (1) GR3034396T3 (de)
HK (1) HK1013816A1 (de)
HU (2) HUT71419A (de)
IL (1) IL105464A (de)
NO (1) NO306946B1 (de)
NZ (1) NZ252098A (de)
PT (1) PT638073E (de)
RU (1) RU2114106C1 (de)
SK (1) SK281613B6 (de)
WO (1) WO1993022293A1 (de)
ZA (1) ZA932840B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
WO2002068409A1 (en) * 2001-02-23 2002-09-06 Merck & Co., Inc. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
CA2467337A1 (en) 2001-12-21 2003-07-10 H. Lundbeck A/S Aminoindane derivatives as serotonin and norepinephrine uptake inhibitors
IS7282A (is) * 2001-12-21 2004-05-21 H. Lundbeck A/S Amínóindan afleiður sem serótónín og noradrenalínupptökuhindrar
PL199016B1 (pl) † 2002-06-20 2008-08-29 Adamed Sp Z Oo Sposób wytwarzania olanzapiny
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
TWI403505B (zh) * 2003-08-18 2013-08-01 Lundbeck & Co As H 反－４－（（１ｒ，３ｓ）－６－氯－３－苯基二氫茚－１－基）－１，２，２－三甲基哌之琥珀酸鹽和丙二酸鹽及其作為藥物之用途
AU2004265021B2 (en) 2003-08-18 2010-05-27 H. Lundbeck A/S Succinate and malonate salt of trans-4-(IR,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
MX2007009816A (es) * 2005-02-16 2007-09-07 Lundbeck & Co As H Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina.
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
TW200819426A (en) 2006-08-31 2008-05-01 Lundbeck & Co As H Novel indane compounds
KR20110021754A (ko) * 2008-05-07 2011-03-04 하. 룬드벡 아크티에셀스카브 인지 결함 치료 방법
CA2732613A1 (en) * 2008-10-03 2010-04-08 H. Lundbeck A/S Oral formulation
PE20120881A1 (es) * 2009-04-30 2012-08-24 AbbVie Deutschland GmbH and Co KG Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
TW201102370A (en) 2009-07-07 2011-01-16 Lundbeck & Co As H Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine
CN104496780A (zh) 2010-11-09 2015-04-08 株式会社钟化 卤化茚酮类及使用其的光学活性茚满酮类或光学活性茚满醇类的制造方法
CN103429577A (zh) 2011-01-07 2013-12-04 H.隆德贝克有限公司 4-((1r,3s)-6-氯-3-苯基-茚满-1-基)-1,2,2-三甲基哌嗪和1-((1r,3s)-6-氯-3-苯基-茚满-1-基)-3,3-二甲基哌嗪的拆分方法
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
SI2720989T1 (sl) * 2011-06-20 2016-11-30 H. Lundbeck A/S Devterirani 1-piperazino-3-fenil indani za zdravljenje shizofrenije
US20210147366A1 (en) * 2018-04-06 2021-05-20 H. Lundbeck A/S Process for preparation of 2,2-dimethylpiperazine
US20210395208A1 (en) 2018-10-29 2021-12-23 H. Lundeck A/S Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038395A (en) * 1973-06-25 1977-07-26 Kefalas A/S Compositions of and method of treating with the alpha-isomer of 2-chloro-9-[3'-(N'-2-hydroxyethylpiperazino-N)-propylidene]-thiaxanthene, carboxylic acid esters thereof and acid addition salts of these compounds
GB1469108A (en) * 1973-06-25 1977-03-30 Kefalas As Thiaxanthene derivative
IE50867B1 (en) * 1980-02-29 1986-08-06 Kefalas As Indane derivatives
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
GB8427125D0 (en) * 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
EP0202322B1 (de) * 1984-12-03 1991-05-08 Hughes Aircraft Company Variabler linsen- und doppelbrechungskompensator für kontinuierlichen betrieb
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
GB8628644D0 (en) * 1986-12-01 1987-01-07 Lunbeck A S H Intermediates
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
EP0302423A3 (de) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-Phenyl-3-(1-piperazinyl)-1H-Indazole, Verfahren und Zwischenprodukte zu deren Herstellung und deren Anwendung als Arzneimittel
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
EP0507863A4 (en) * 1989-12-28 1993-07-07 Virginia Commonwealth University Sigma receptor ligands and the use thereof
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater

Also Published As

Publication number Publication date
US5807855A (en) 1998-09-15
KR950701323A (ko) 1995-03-23
DK0638073T3 (da) 2000-11-06
HUT71419A (en) 1995-11-28
NO944090L (no) 1994-12-20
AU669709B2 (en) 1996-06-20
KR100267635B1 (ko) 2000-11-01
NO944090D0 (no) 1994-10-27
HK1013816A1 (en) 1999-09-10
JPH07505895A (ja) 1995-06-29
CL2003002050A1 (es) 2005-01-07
SK129394A3 (en) 1995-05-10
ES2148227T3 (es) 2000-10-16
NO306946B1 (no) 2000-01-17
HU211909A9 (en) 1996-01-29
IL105464A0 (en) 1993-08-18
HU9403098D0 (en) 1994-12-28
FI945042A (fi) 1994-10-26
CA2134566C (en) 2004-08-10
EP0638073B1 (de) 2000-06-21
DK55192D0 (da) 1992-04-28
CA2134566A1 (en) 1993-11-11
RU2114106C1 (ru) 1998-06-27
JP3255416B2 (ja) 2002-02-12
ZA932840B (en) 1993-11-23
GR3034396T3 (en) 2000-12-29
AU4059993A (en) 1993-11-29
CZ281676B6 (cs) 1996-12-11
IL105464A (en) 1998-01-04
EP0638073A1 (de) 1995-02-15
DE69328901D1 (de) 2000-07-27
RU94045948A (ru) 1996-09-10
CZ261994A3 (en) 1995-05-17
FI945042A0 (fi) 1994-10-26
SK281613B6 (sk) 2001-05-10
WO1993022293A1 (en) 1993-11-11
DE69328901T2 (de) 2001-01-11
NZ252098A (en) 1996-05-28
ATE194003T1 (de) 2000-07-15
PT638073E (pt) 2000-11-30

Similar Documents

Publication Publication Date Title
FI113862B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 1-piperatsino-1,2-dihydroindeenijohdannaisten valmistamiseksi
DK174161B1 (da) Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem
US3813384A (en) Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
EP0375210A1 (de) Pyrazoloisoquinoline-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
KR900002246B1 (ko) 테트라하이드로-2-헤테로사이클로알킬-피리도[4,3-b]인돌 및 그의 제조방법
US5066803A (en) 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazines
FI71936B (fi) Foerfarande foer framstaellning av neuroleptiskt aktiva 2-substituerade-8-fluor-5-(4-fluorfenyl)-2,3,4,4a 5,9b-hexahydro-4a 9b-trans-1h-pyrido/4,3-b/indolderivat
EP0233413B1 (de) 3-(2-Aminoethyl)indol und -indolinderivate, Verfahren zu ihrer Herstellung und diese Derivate enthaltende pharmazeutische Zusammensetzungen
FR2530632A1 (fr) Nouveaux derives substitues du 2,5-diamino 1,4-diazole, leurs procedes de preparation et les compositions pharmaceutiques en renfermant
FI86301B (fi) Foerfarande foer framstaellning av farmaceutiskt anvaendbara naftoxaziner.
US5109135A (en) 2- or 3-aminomethyl-4-amino-3,4-dihydro-2H-1,4-benzoxazine intermediates
WO2009034581A1 (en) Substituted indolyl compounds and their use as 5-ht6 ligands
JPS6130588A (ja) ベンゾ〔ｃ〕〔１，８〕ナフチリジン、その製造方法及びその使用、並びにこれらの化合物を含有する調製剤
AU607354B2 (en) Antipsychotic 4-(4-(3-benzisothiazolyl)-1-piperazinyl) butyl bridged bicyclic imides
EP0375536B1 (de) 1,7'-[Imidazo-[1,2-a]pyridin]5'-(6'H)one-Derivate und Verfahren zu deren Herstellung
EP0746556B1 (de) Trizyklische verbindungen mit affinität für den 5-ht1a rezeptor
FI66365C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1,4-cykloalkano-oxazepiner vari oxazepinringen och cykloalkanogruppen aer i cis-staellningen i foerhaollande till varandra
JP2586552B2 (ja) ピペラジン化合物
NO179409B (no) Psykoaktive 4-[4-eller 6-(trifluormetyl-2-pyridinyl)Å-1-piperazinyl-alkylsubstituerte laktamer og anvendelse derav

Legal Events

Date Code Title Description
MA Patent expired